Functional cure of CHB encounters resmetirom

Author’s names:

Nai-Bin Yang1,2, Wai-Kay Seto3,4,5, Ming-Hua Zheng6,7,*

Institutions:

1Department of Hepatology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China;
2Ningbo Key Laboratory of Translational Medicine Research on Gastroenterology and Hepatology, Ningbo, Zhejiang, China;
3Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China;
4Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, Guangzhou, China;
5State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China;
6MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China;
7Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China.
Corresponding author:

Ming-Hua Zheng, MD, PhD

MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

E-mail: zhengmh@wmu.edu.cn; Tel: (86) 577-55579611; fax: (86) 577-55578522

Words count: 366

Conflict of Interest:

Ming-Hua Zheng has received honoraria for lectures from AstraZeneca, Hisky Medical Technologies and Novo Nordisk, consulting fees from Boehringer Ingelheim, and serves as a consultant for Eieling Technology.

Financial support:

This paper was funded by grants from the National Natural Science Foundation of China (82070588, 82370577), National Key R&D Program of China (2023YFA1800801).
On March 14, 2024, the US FDA approved resmetirom for fast-track treatment of adult patients with metabolic dysfunction associated with steatohepatitis (MASH) with fibrosis, making it the world's first approved drug. Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) are the most prevalent chronic liver diseases worldwide,¹ and concurrent MASLD is common in patients with CHB, with a prevalence of 29.6-34.9%.² When using resmetirom to treat MASH patients with CHB, it is important to consider the potential impacts of hepatic steatosis in improving functional cure of CHB.

**Hepatic steatosis is beneficial to functional cure of CHB by decreasing HBV DNA levels and increasing HBsAg seroclearance**

Both CHB and MASLD can lead to hepatic inflammation and liver fibrosis, increasing the risk of adverse liver outcomes.³ However, CHB patients with concurrent steatosis tend to have lower HBV activity, including lower proportions of hepatitis B e antigen (HBeAg) positivity, lower serum HBV DNA levels, as well as higher rates of hepatitis B surface antigen (HBsAg) seroclearance, and are more likely to achieve functional cure.⁴ ⁵ Studies on animals and cells show that hepatic steatosis can decrease HBV activity and induce lower levels of HBsAg, HBeAg, and HBV DNA.⁶ The molecular mechanism might be explained as liver fat activating innate immunity, disrupting the liver's metabolic environment, and increasing liver cell apoptosis, reducing HBV survival.⁷
Can resmetirom potentially decrease functional cure of CHB?

In the phase 3, randomized, controlled trial of resmetirom in MASH with liver fibrosis, both the resmetirom treatment groups significantly improved hepatic steatosis and inflammation. It is unclear if resmetirom can be used to treat MASH patients with concurrent CHB. We recommend the answer is YES due to both CHB and MASLD can increase the risk of adverse liver outcomes, however close monitoring of HBV activity is necessary as resmetirom could potentially alleviate steatosis and increase HBV activity. Further research is needed to determine if more aggressive antiviral therapy (e.g. entecavir combined with tenofovir, or nucleotide analogues combined with interferon, etc.) is necessary when using resmetirom treating MASH patients with concurrent CHB. The field remains blank, and more clinical data are needed to reveal the answers and guide drug treatment choices in this large population.
References


